Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (Otsuka)

Protocol Name: Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN) Sponsor: Otsuka Indication: IgA Nephropathy Primary Investigator: Dr. Bernard Fischbach Location:Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >